nach oben

Journal of Nuclear Cardiology

Erschienen in:

01.08.2019 | Editorial

Can positron emission tomography help stratify the risk of sudden cardiac death in patients with hypertrophic cardiomyopathy?

verfasst von: G. Neal Kay, MD

Erschienen in: Journal of Nuclear Cardiology | Ausgabe 4/2019

Einloggen, um Zugang zu erhalten

Excerpt

Hypertrophic cardiomyopathy (HCM) is a heterogeneous cardiac disease based on autosomal genetic mutations of genes coding for proteins involving the sarcomeres and myofilament elements.1‐4 The clinical consequences of these mutations are widely variable, ranging from patients remaining totally asymptomatic to the most dreaded outcome, sudden cardiac death (SCD) which accounts for over 50% of deaths in this population.4 Despite considerable advances in our understanding of the genetic basis for this disease and its relation to the clinical course of patients with these mutations,5 there remains considerable heterogeneity in the risk of adverse outcomes. This is especially relevant as a clinician tries to prevent sudden cardiac death for an individual patient while minimizing the burden of therapy.6 …

Gersh BJ, Maron BJ, Bonow RO, Dearani JA, Fifer MA, Link MS, Naidu SS, Nishimura RA, Ommen SR, Rakowski H, Seidman CE, Towbin JA, Udelson JE, Yancy CW. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy. J Thorac Cardiovasc Surg 2011;142:153-203.CrossRef

Maron BJ, Maron MS. Contemporary strategies for risk stratification and prevention of sudden death with the implantable defibrillator in hypertrophic cardiomyopathy. Heart Rhythm 2016;13:1155-65.CrossRefPubMed

Maron MS, Olivotto I, Maron BJ, Prasad SK, Cecchi F, Udelson JE, Camici PG. The case for myocardial ischemia in hypertrophic cardiomyopathy. J Am Coll Cardiol 2009;54:866-75.CrossRefPubMed

Maron BJ, Olivotto I, Spirito P, et al. Epidemiology of hypertrophic cardiomyopathy-related death: Revisited in a large non-referral-based patient population. Circulation 2000;102:858-64.CrossRefPubMed

Maurizi N, Passantino S, Spaziani G, Girolami F, Arretini A, Targetti M, Pollini I, Tomberli A, Pradella S, Calabri GB, Vinattieri V, Bertaccini B, Leone O, De Simone L, Rapezzi C, Marchionni N, Cecchi F, Favilli S, Olivotto I. Long-term outcomes of pediatric-onset hypertrophic cardiomyopathy and age-specific risk factors for lethal arrhythmic events. JAMA Cardiol 2018. https://doi.org/10.1001/jamacardio.2018.0789.CrossRefPubMedPubMedCentral

Marrakchi S, Kammoun I, Bennour E, Laroussi L, Kachboura S. Risk stratification in hypertrophic cardiomyopathy. Herz 2018. https://doi.org/10.1007/s00059-018-4700-8.CrossRefPubMed

Maron BJ, Spirito P, Shen WK, Haas TS, Formisano F, Link MS, Epstein AE, Almquist AK, Daubert JP, Lawrenz T, Boriani G, Estes NA 3rd, Favale S, Piccininno M, Winters SL, Santini M, Betocchi S, Arribas F, Sherrid MV, Buja G, Semsarian C, Bruzzi P. Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy. JAMA 2007;298:405-12.CrossRefPubMed

Maron BJ, Casey SA, Olivotto I, Sherrid MV, Semsarian C, Autore C, Ahmed A, Boriani G, Francia P, Winters SL, Giudici M, Koulova A, Garberich R, Rowin EJ, Sears SF, Maron MS, Spirito P. Clinical course and quality of life in high-risk patients with hypertrophic cardiomyopathy and implantable cardioverter-defibrillators. Circ Arrhythm Electrophysiol 2018;11:e005820. https://doi.org/10.1161/CIRCEP.117.005820.CrossRefPubMed

Al-Khatib SM, Stevenson WG, Ackerman MJ, Bryant WJ, Callans DJ, Curtis AB, Deal BJ, Dickfeld T, Field ME, Fonarow GC, Gillis AM, Hlatky MA, Granger CB, Hammill SC, Joglar JA, Kay GN, Matlock DD, Myerburg RJ, Page RL. 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. J Am Coll Cardiol 2017. https://doi.org/10.1016/j.jacc.2017.10.054.CrossRefPubMedPubMedCentral

10.

Spirito P, Maron BJ. Relation between extent of left ventricular hypertrophy and occurrence of sudden cardiac death in hypertrophic cardiomyopathy. J Am Coll Cardiol 1990;15:1521-6.CrossRefPubMed

11.

Christiaans I, van Engelen K, van Langen IM, et al. Risk stratification for sudden cardiac death in hypertrophic cardiomyopathy: Systematic review of clinical risk markers. Europace 2010;12:313-21.CrossRefPubMed

12.

Spirito P, Autore C, Rapezzi C, et al. Syncope and risk of sudden death in hypertrophic cardiomyopathy. Circulation 2009;119:1703-10.CrossRefPubMed

13.

Viswanathan K, Suszko AM, Das M, et al. Rapid device-detected nonsustained ventricular tachycardia in the risk stratification of hypertrophic cardiomyopathy. Pacing Clin Electrophysiol 2016;39:642-51.CrossRefPubMed

14.

Olivotto I, Maron BJ, Montereggi A, et al. Prognostic value of systemic blood pressure response during exercise in a community-based patient population with hypertrophic cardiomyopathy. J Am Coll Cardiol 1999;33:2044-51.CrossRefPubMed

15.

Minami Y, Haruki S, Kanbayashi K, Itani R, Hagiwara N. B-type natriuretic peptide and risk of sudden death in patients with hypertrophic cardiomyopathy. Heart Rhythm 2018. https://doi.org/10.1016/j.hrthm.2018.04.030.CrossRefPubMed

16.

Sorajja P, Nishimura RA, Ommen SR, et al. Use of echocardiography in patients with hypertrophic cardiomyopathy: Clinical implications of massive hypertrophy. J Am Soc Echocardiogr 2006;19:788-95.CrossRefPubMed

17.

Maron MS, Olivotto I, Betocchi S, et al. Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. N Engl J Med 2003;348:295-303.CrossRefPubMed

18.

Maron BJ, Rowin EJ, Casey SA, et al. Hypertrophic cardiomyopathy in adulthood associated with low cardiovascular mortality with contemporary management strategies. J Am Coll Cardiol 2015;65:1915-28.CrossRefPubMed

19.

Choudhury L, Mahrholdt H, Wagner A, Choi KM, Elliott MD, Klocke FJ, et al. Myocardial scarring in asymptomatic or mildly symptomatic patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 2002;40:2156-64.CrossRefPubMed

20.

Bruder O, Wagner A, Jensen CJ, Schneider S, Ong P, Kispert EM, et al. Myocardial scar visualized by cardiovascular magnetic resonance imaging predicts major adverse events in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 2010;56:875-87.CrossRefPubMed

21.

Chan RH, Maron BJ, Olivotto I, Pencina MJ, Assenza GE, Haas T, Lesser JR, Gruner C, Crean AM, Rakowski H, Udelson JE, Rowin E, Lombardi M, Cecchi F, Tomberli B, Spirito P, Formisano F, Biagini E, Rapezzi C, De Cecco CN, Autore C, Cook EF, Hong SN, Gibson CM, Manning WJ, Appelbaum E, Maron MS. Prognostic value of quantitative contrast-enhanced cardiovascular magnetic resonance for the evaluation of sudden death risk in patients with hypertrophic cardiomyopathy. Circulation 2014;130:484-95.CrossRefPubMed

22.

Green JJ, Berger JS, Kramer CM, Salerno M. Prognostic value of late gadolinium enhancement in clinical outcomes for hypertrophic cardiomyopathy. J Am Coll Cardiol Imaging 2012;5:370-7.CrossRef

23.

O’Hanlon R, Grasso A, Roughton M, Moon JC, Clark S, Wage R, et al. Prognostic significance of myocardial fibrosis in hypertrophic cardiomyopathy. J Am Coll Cardiol 2010;56:867-74.CrossRefPubMed

24.

Maron MS, Appelbaum E, Harrigan CJ, Buros J, Gibson CM, Hanna C, et al. Clinical profile and significance of delayed enhancement in hypertrophic cardiomyopathy. Circulation 2008;1:184-91.PubMed

25.

Basso C, Thiene G, Corrado D, Buja G, Melacini P, Nava A. Hypertrophic cardiomyopathy and sudden death in the young: Pathologic evidence of myocardial ischemia. Hum Pathol 2000;31:988-98.CrossRefPubMed

26.

Dilsizian V, Bonow RO, Epstein SE, Fananapazir L. Myocardial ischemia detected by thallium scintigraphy is frequently related to cardiac arrest and syncope in young patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 1993;22:796-804.CrossRefPubMed

27.

Cecchi F, Olivotto I, Gistri R, Lorenzoni R, Chiriatti G, Camici PG. Coronary microvascular dysfunction and prognosis in hypertrophic cardiomyopathy. N Engl J Med 2003;349:1027-35.CrossRefPubMed

28.

Lu DY, Yalçin H, Yalçin F, Zhao M, Sivalokanathan S, Valenta I, Tahari A, Pomper MG, Abraham TP, Schindler TH, Abraham MR. Stress myocardial blood flow heterogeneity is a positron emission tomography biomarker of ventricular arrhythmias in patients with hypertrophic cardiomyopathy. Am J Cardiol 2018;121:1081-9.CrossRefPubMedPubMedCentral

29.

Maron BJ, Epstein SE, Roberts WC. Hypertrophic cardiomyopathy and transmural myocardial infarction without significant atherosclerosis of the extramural coronary arteries. Am J Cardiol 1979;43:1086-102.CrossRefPubMed

30.

Maron BJ, Wolfson JK, Epstein SE, Roberts WC. Intramural (“small vessel”) coronary artery disease in hypertrophic cardiomyopathy. J Am Coll Cardiol 1986;8:545-57.CrossRefPubMed

31.

O’Gorman DJ, Sheridan DJ. Abnormalities of the coronary circulation associated with left ventricular hypertrophy. Clin Sci (Lond) 1991;81:703-13.CrossRef

32.

Roberts WC, Ferrans VJ. Pathologic anatomy of the cardiomyopathies. Idiopathic dilated and hypertrophic types, infiltrative types, and endomyocardial disease with and without eosinophilia. Hum Pathol 1975;6:287-342.CrossRefPubMed

33.

Bengel FM, Higuchi T, Javadi MS, Lautamaki R. Cardiac positron emission tomography. J Am Coll Cardiol 2009;54:1-15.CrossRefPubMed

34.

Olivotto I, Girolami F, Sciagra R, Ackerman MJ, Sotgia B, Bos JM, et al. Microvascular function is selectively impaired in patients with hypertrophic cardiomyopathy and sarcomere myofilament gene mutations. J Am Coll Cardiol 2011;58:839-48.CrossRefPubMed

35.

Castagnoli H, Ferrantini C, Coppini R, Passeri A, Baldini K, Berti V, et al. Role of quantitative myocardial positron emission tomography for risk stratification in patients with hypertrophic cardiomyopathy: A 2016 reappraisal. Eur J Nucl Med Mol Imaging 2016;43:2413-22.CrossRefPubMed

36.

Bravo PE. Is there a role for cardiac positron emission tomography in hypertrophic cardiomyopathy? J Nucl Cardiol 2018.

Titel: Can positron emission tomography help stratify the risk of sudden cardiac death in patients with hypertrophic cardiomyopathy?
verfasst von: G. Neal Kay, MD
Publikationsdatum: 01.08.2019
Verlag: Springer International Publishing
Erschienen in: Journal of Nuclear Cardiology / Ausgabe 4/2019
Print ISSN: 1071-3581
Elektronische ISSN: 1532-6551
DOI: https://doi.org/10.1007/s12350-018-1299-3

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Can positron emission tomography help stratify the risk of sudden cardiac death in patients with hypertrophic cardiomyopathy?

Excerpt

Neu im Fachgebiet Kardiologie

Die „Zehn Gebote“ des Endokarditis-Managements

Strenge Blutdruckeinstellung lohnt auch im Alter noch

Sind Frauen die fähigeren Ärzte?

Dihydropyridin-Kalziumantagonisten können auf die Nieren gehen

Update Kardiologie

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2019

Computed tomography continues to be the preferred tomographic imaging technology for patients with cardiac implantable electronic devices despite a potential risk of electrical interference by irradiation

Detection of chemotherapy-induced cardiotoxicity with antimyosin pretargeted imaging

Is there a role for cardiac positron emission tomography in hypertrophic cardiomyopathy?

Cardiovascular disease in the literature: A selection of recent original research papers

Do we need diagnostic strategies enhanced with genetic information for ischemic heart disease?

Potential effects of low-dose average CT on cardiac implantable electronic devices

Neu im Fachgebiet Kardiologie

Die „Zehn Gebote“ des Endokarditis-Managements

Strenge Blutdruckeinstellung lohnt auch im Alter noch

Sind Frauen die fähigeren Ärzte?

Dihydropyridin-Kalziumantagonisten können auf die Nieren gehen

Update Kardiologie